Divya has worked with Alvogen since 2009 and formally joined the company in 2012.  He was appointed as the CEO of Alvogen and its affiliate Almaject in January 2026. Divya has held various pharmaceutical leadership positions during the past 30 years, including Executive Chairman of Actavis in the US.  In addition, he has more than 20 years of experience in healthcare investing with a focus on the pharmaceutical and longevity-science sectors. For Alvogen, he provides a proven track record as a senior leader in the generic pharmaceutical space.

Divya Patel, CEO

Tunie serves as the Chief Financial Officer. She has 20 years of Finance experience, with over 10 years in the pharmaceutical industry. She was an integral part of the turnaround and growth of Par and its successful sale to Endo in 2015.

Most recently, Tunie was the Generics Business Controller for Endo Pharmaceuticals where she was responsible for generics consolidated financial statements, global policy and processes, and alliance management. She has worked on several key organizational-wide strategic initiatives including leading the finance integration for Par and a number of restructuring initiatives resulting in bottom line savings.

Tunie is a Certified Public Accountant in the state of New Jersey and holds a Bachelor’s degree in Accounting from Seton Hall University.

Tunie Zaku

Rama Yarasani joined Almaject in September 2018 and is responsible for management of all aspects of CMS, Clinical Pharmacology, Regulatory Affairs, Project Management, Commercial Validation and Product Transfers.  He has almost thirty years of experience in the pharmaceutical industry, primarily in 505(b)(2) and complex generic products.

Rama holds a Bachelors degree in Pharmaceutical Sciences, a Masters degree in Pharmaceutics and a PhD in Pharmaceutics all from Andhra University in India.

Rama Yarasani

Carl joined Almaject in June 2022 as Senior Vice President Supply Chain and leads all facets of Supply Planning and Third Party supply networks to ensure optimal inventory levels to support robust Customer Service expectations.  He is an accomplished Life Science leader with nearly thirty years of comprehensive global supply chain and operational management responsibilities in both the pharmaceutical and device industry.  Carl is well versed in managing complex projects, directing cross-functional teams, championing compliance, and working with Regulatory agencies.  Some successes from his career include: Major product launches, acquisitions and divestitures, U.S. FDA drug and device warning letter remediation, and complex technical transfer.  His career spans progressive leadership roles at Abbott Laboratories, Hospira, Pfizer and Mayne Pharma.    

Carl holds a Bachelor of Science degree in Biology from North Carolina Wesleyan University.

Carl Turner

As Vice President of Information Technology for the US Region, Neha’s roles include supporting Almaject’s growth by partnering with the company's business units to fuel innovation and provide strategic insights through the use of cutting-edge technology. Through her efforts, Neha brings daily IT efficiency to all staff.

Neha joined Almaject in 2015 and has more than 20 years of extensive Information Technology experience in the pharmaceutical, telecommunication and banking industries. Prior to joining Almaject, she ensured superior IT processes at Daiichi Sankyo Pharma. Neha holds a Bachelor’s of Science degree from the New Jersey Institute of Technology.

Neha Patel

As Human Resources Director, Emily is responsible for all strategic initiatives related to employee development, engagement and retention in the US region. Her role includes supporting staff growth by developing and implementing comprehensive reward, training and leadership programs; recruiting and onboarding new employees to the company; and ensuring adherence to government and legal requirements.

Emily is an accomplished Human Resources professional with extensive experience in the pharmaceutical, consumer goods, and manufacturing industries. Prior to Alvogen, Emily held progressive roles at Novartis, Gerber Products, Viacom and Occidental Chemical. Emily holds a Bachelor’s Degree in Communications from Northwestern University.

Emily Smith

Travis joined Alvogen in 2018 to lead the commercial business for our generics portfolio in the US Region.

He brings 20 years of experience from the pharmaceutical industry and has a proven track record of commercial leadership at companies including Bausch & Lomb, Cadista, URL/Mutual and Watson Pharmaceuticals. At G&W Laboratories, he led the Sales and Marketing organization to successfully launch new products while maintaining strategic business in the constantly changing US market.

Travis holds a Bachelor’s degree in Business Administration from Brigham Young University in Provo, Utah and a MBA in Finance and Marketing from the University of South Florida in Tampa.

Travis Roberts

Kate joined Alvogen in September 2022 as the Vice President of Customer Contracting and Trade Relations, leading commercial operations including pricing and contracting, reverse logistics, customer service, rebates, chargebacks, and trade relations for the company.  With over 20 years of experience, Kate has held progressively responsible roles across marketing and national accounts at Mallinckrodt, Dr. Reddy’s, and Rising Pharmaceuticals. Most recently, as a Director at PwC, Kate led consulting engagements in pricing and profitability across the branded pharma, med technology and device industries, driving substantial business improvements.  Kate holds a Bachelor's Degree in Business Administration with a concentration in Supply Chain Management from the University of Illinois Urbana-Champaign.

Kate Neely

Almaject is a subsidiary of Alvogen.  Almaject's leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new injectable generic pharmaceutical products quickly and safely to market.